The effects of doxycycline (DOX) and streptomycin (SM) treatment of Brucella melitensis infected mice on humoral immune response were examined. In female BALB/c mice, DOX was administered at a dose of 50 mg/kg/ 12 h, for 2 I or 45 consecutive days, alone or combined with SM (10 mg/kg/ 12 h) for 14 days. All treatments induced a significant increase in specific IgG levels (ELISA and CIEP) against LPS and cytosolic antigens of Brucella during treatment. This was not related with therapeutic failure or relapse since all treatments induced a significant reduction in the degree of infection.
Introduction
Brucellosis remains a public health problem world-wide, predominantly in the Mediterranean and in some developing countries. Bruceh belongs to the group of intracellular bacteria, and this fact seems to be responsible for the long duration of the disease and the high incidence of relapses [l-3] . In addition to observations made by clinicians, the diagnosis of human brucellosis is based on microbiological and serological laboratory tests. Although the only definitive test is bacteriological isolation of Brucelh, cultures are not always positive [4] , and serological methods are routinely used as indirect proof for diagnosis. This presents some problems, such as the false diagnosis of relapse or reinfection of individuals who are serologically positive and oligo-symptomatic, mainly when the serological study is performed soon after therapy.
The most adequate antibiotic treatment for human brucellosis is the combination of doxycycline (DOX) with streptomycin (SM) [l-3] . The aim of this work was, therefore, to evaluate the influence of this antibiotic treatment on the serology, studying the specific IgG response against LPS and cytosolic antigens in B. melitensis infected mice.
Materials and methods

Drugs
orally by using a syringe coupled with a special gauge to avoid hurting the throat. SM was administered intraperitoneally.
Animals
Female BALB/c mice (20 f 2 g) (Charles River, Spain) were used. Mice were held in a safety cabinet at constant humidity and temperature, receiving food and water ad libitum.
Challenge organisms
The organism used was the virulent strain B. melitensis 16M ATCC 23456 (reference strain of biotype 1). Before being used in the infection studies, the smoothness of the strains was ensured with the dissociation test [5] . The infective doses were prepared by appropriate dilution of the stock suspension in sterile saline, and the number of colony forming units (cfu) was determined. Therefore diluted bacterial suspensions were plated onto tryptic soy agar and the number of colonies were counted after incubation for 4 to 5 days at 37°C.
Infection and treatment studies
BALB/c mice were infected i.p. with 9.2 X IO5 cfu of B. melitensis 16M. Thirty days later, the infected animals were randomised in five groups of six mice per group. In order to establish the normal splenic infection evolution during the 224 days that the experiment lasted, a non-treated control group was included. The four other groups received one of the following therapeutic regimens: DOX (oral, 50 mg/kg/l2 h) for 21 days, alone or in combination with SM (i.p., 10 mg/kg/l2 h) for 14 days; DOX (oral, 50 mg/kg/l2 h) for 45 days, alone or in combination with SM (i.p., 10 mg/kg/l2 h) for 14 days. The treatments were started on day 31, during the plateau phase of the infection. At preestablished days after treatment (Table 1) , the corresponding groups of mice were anaesthetised (ether) and blood samples were taken. The samples were serologically tested individually.
Mice were killed by cervical dislocation and their spleens (target organ in murine brucellosis) were homogenised, diluted serially, and plated onto tryptic soy agar to determine the number of viable Brucella cells. 
Antigens and serological tests
LPS fraction was obtained from B. melitensis 16 M as described previously [6] . Briefly, washed cells were extracted with distilled water (30 g wet weight in 100 ml) at 120°C for 15 min. The extract was clarified by centrifugation and precipitated first with three volumes of ethanol and then with two additional volumes of the same solvent.
(2,2'-azino-bis, 3 ethylbenzthiazoline-6-sulfonic acid) was used as the cromophore in the developing reaction. The highest dilution with an absorbance 0.2 units (OD 405 nm, spectrophotometer Titertek Multiskan, Flow Labs., Helsinki, Finland) greater than the control (no serum added) was taken as the titer. The assay was performed in triplicate and the mean value was taken for evaluation.
The cytosolic fraction was obtained from logarithmic cells of the rough strain B. melitensis 115 to avoid the detection of antibodies against smooth-LPS, as described elsewhere [6] . Briefly, the cells were disintegrated with glass beads in an MSK cell homogeneizer (B. Braun Mesulgen AG, Leinfelden, Germany). Cell envelopes were sedimented (80000 X g for 2 h at 4°C) and the supematant was held at 4°C for 24 h before being ultracentrifuged again under the same conditions, and then collecting the supernatant that represents the cytosolic fraction.
Counterimmunoelectrophoresis (CIEP)
2.6. ELISA ELISA titrations were performed by a microplate assay. Five pg of LPS per well were fixed on polystyrene plates (Maxisorb, Nunc) in carbonate buffer (0.06 M, pH 9.6) overnight at 37°C. The assay was performed by the indirect method of Voller et al. [7] , with a peroxidase-conjugated immunoglobulin fraction of rabbit anti-mouse IgG, H and L chains (Nordic Labs., Tilburg, the Netherlands).
ABTS CIEP was performed according to the procedure described by Diaz et al. [8] . Glass slides (10 X 15 cm) were coated with 2 mm thick gel of 1% agarose (Agarose A, Ph armacia Fine Chemical) in 20 mM Verona1 (pH 8.61, and 3 mm diameter antigen and serum wells were punched 1 cm apart. Anodic wells were filled up with the sera, and 15 ~1 of cytosol (1 mg/ml) were dispensed in the cathodic wells. Electrophoresis was performed at constant voltage of 90 V/cm, for 60 min. In order to eliminate unspecific bands, the slides were incubated for 30 min in 5% monosodium citrate. The stain of the precipitin bands was performed with Coomassie brilliant blue R 0.5%. The results were expressed by titers. and number of bands developed.
Statistical analysis
Differences in cfu, and serological data between the treated and untreated groups were evaluated by ELISA titers were transformed to integer from five to twelve corresponding to titers of 320 to 40960, respectively. All analyses were conducted with version II Statview SE software (Abacus Concepts, Inc., Berkeley, CA). P values of 0.05 or less were considered statistically significant. Table 1 shows the B. melitensis infection evolution (cfu/spleen) for each treatment compared with the untreated control group. The statistical analysis confirmed that from day 43 post-infection, all treatments produced a significant reduction in the infection. Besides, when DOX was administered for 45 days, it 'cured' all the animals from day 78. The combination with SM did not improve the efficacy of any treatment. Table 2 shows the ELISA titers of IgG anti-LPS for the different treatments and control group. There were no differences among treatments. However, until the end of therapy the treated animals presented titers of IgG anti-LPS higher, even more than three times dilution, than the control infected-untreated group; from that point (day 76 post-infection), the titers became slightly higher, but not significantly different. Fig. 1 a CIEP titers were transformed from 1 to 6 corresponding to titers of 2 to 64, respectively.
Results
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* : more than four precipitin bands.
the comparative evolution of titers for control and DOX treated animals. Similar results were obtained testing the level of specific IgG against cytosolic fraction of Brucella by CIEP; however, only a limited rise of one dilution was observed. In addition, the number of precipitation bands were clearly increased during the treatment period (Table 3) .
Discussion
The diagnosis of human brucellosis based on serology is generally easy to perform, although its interpretation is not always correct. One of the most difficult problems originates in the existence of individuals who are asymptomatic and serologically positive. These patients can be wrongly classified in the category of therapeutic failure or recidive, and it usually happens when the serological analysis is made too promptly after therapy. Given the high incidence of relapses after brucellosis treatment [ l-31, and the fact that recurrence of clinical symptoms is considered a relapse when the IgG titer rises [9] , this phenomenon acquires a great importance in the diagnosis.
On the other hand, research on the immunomodu-latory properties of antimicrobial agents is important along with the study of their bactericidal properties. Results suggest that antimicrobials may interfere with the functions of phagocytic cells [IO] . Besides, it has been described that some treatments may retard or even diminish the antibody formation, resulting in an increase in the rate of relapses of certain infections [11, 12] . The results obtained in our experimental model 'BALB/c-B.
melitensis' demonstrate that none of the treatments tried had an adverse effect on the antibody production, compared with the infected-untreated group. On the contrary, all treatments induced a significant increase of the specific IgG levels (ELISA and CIEP) against Brucella LPS and cytosol antigens during therapy. This increase in antibody levels was not related to therapeutic failure or relapse because all treatments led to a significant reduction in the degree of infection. After treatment, the animals presented titers not significantly different compared to the infected-untreated ones. These results could be explained considering the nature of 'antigen presenting cells' of the Bruce&z host cells. The bactericidal effect of the antimicrobial inside the phagocyte will trigger the antigenic processing and the generation of the specific humoral response.
Therefore, these data will be in agreement with the data obtained in human brucellosis where cured patients often show higher and persistent titers [ 13,141. Frequently, because of a clear misinterpretation, these patients will receive further treatments as long as they do not decrease their specific antibody levels against Brucella.
The results presented here strongly indicate that, if these data are extrapolated to the human host, the presence of antibodies does not mean unequivocally active infection by Brucella, and therefore serological results must be always interpreted in the light of clinical and bacteriological data.
